Healthcare Equipment and Supplies
Company Overview of Alcon, Inc.
Alcon, Inc. develops and manufactures eye care products for eye care professionals and their patients. It offers surgical products, which include technologies and devices for cataract, retinal, glaucoma, and refractive surgery; advanced technology intraocular lenses to treat cataracts and refractive errors, such as presbyopia and astigmatism; and advanced viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery. The company also provides pharmaceutical products for elevated intraocular pressure caused by glaucoma; anti-inflammatories; anti-infective to aid in the treatment of bacterial infections and bacterial conjunctivitis; oph...
6201 South Freeway
Fort Worth, TX 76134-2001
Founded in 1945
Key Executives for Alcon, Inc.
Chief Operating Officer and Executive Vice President
Region President of Latin America and Canada
Region President of United States
Compensation as of Fiscal Year 2014.
Alcon, Inc. Key Developments
Alcon Announces Encouraging Results from Papillary Conjunctivitis Study
May 25 15
Alcon, Inc. announced encouraging results from a new study with CLEAR CARE cleaning and disinfecting solution in patients with contact lens papillary conjunctivitis. This randomized, controlled, investigator-masked, parallel group, multi-site study was conducted in 128 symptomatic contact lens wearers with mild to severe investigator-related palpebral roughness who were habitually using a biguanide-preserved multi-purpose solution. The subjects who used CLEAR CARE Solution during the study showed a significant improvement in lid papillae and symptoms compared to the subjects in the biguanide-preserved multi-purpose solution control group.
Alcon Enhances ORA System and VERION Image Guided System
Apr 22 15
Alcon has unveiled new enhancements to both the ORA System and the VERION image guided system. The VerifEye+ Technology in the ORA System offers the following enhancements to the previous version: provides on demand information to assist in intraoperative decision making and delivers this information to the surgeon via a dynamic reticle visible through the right ocular; and this leads to a more efficient workflow and surgeon usability in the operating room. The 2.6 software in the VERION Image Guided System offers the following enhancements to the previous version: improved functionality and usability in the clinic, at the LenSx Laser and at the microscope in the operating room; compatibility with existing local area network (LAN) based networks configured to connect the VERION components and replace the USB as the primary data transfer process; remote accessibility to the VERION Reference Unit planner database; and upgraded LenStar import and integration with compatible electronic medical record systems (EMRs). The enhancements also include: VERION Quick Snap image capture at the measurement module for surgeons using VERION image-based guidance on astigmatism axis with imported LenStar or manually entered K values; and optical enhancement of the microscope-integrated display (MID) for surgeons in need of improved low light registration and tracking.
Alcon Receives FDA Approval of Pazeo(TM) Solution for Ocular Allergy Itch Relief
Feb 2 15
Alcon has received approval from the US Food and Drug Administration (FDA) of Pazeo(TM) (olopatadine hydrochloride ophthalmic solution) 0.7%, for the treatment of ocular itching associated with allergic conjunctivitis. Pazeo solution is dosed one drop daily, and was approved with efficacy data at 24 hours, post dose. Results from two Conjunctival Allergen Challenge clinical studies showed that Pazeo (olopatadine hydrochloride ophthalmic solution) 0.7%, demonstrated statistically significantly improved relief of ocular itching associated with allergic conjunctivitis at 24 hours post-treatment compared to olopatadine 0.2% (known as Pataday(R) solution). The safety profile of Pazeo solution is comparable to that of olopatadine 0.2%. In the two clinical studies, the most common adverse reactions occurred in 2 to 5% of patients treated with either Pazeo solution or a vehicle. These events were blurred vision, dry eye, superficial punctate keratitis, dysgeusia and abnormal sensation in the eye.
Similar Private Companies By Industry
Recent Private Companies Transactions